Treatment of ER-positive breast cancer cells with α-methyl-dl-tryptophan (α-MT), a selective blocker of SLC6A14, leads to amino acid deprivation, inhibition of the mTOR pathway, activation of autophagy, and induction of cancer cell apoptosis. This evidence concerns the gene MTOR and breast carcinoma.